The cost-effectiveness of a bimekizumab versus IL-17A inhibitors treatment-pathway in patients with active axial spondyloarthritis in Scotland

References

• Reveille JD, Witter JP, Weisman MH. Prevalence of axial spondylarthritis in the United States: estimates from a cross-sectional survey. Arthritis Care Res. 2012;64(6):905–910. doi: 10.1002/acr.21621.
   PubMed Web of Science ®Google Scholar
• National Axial Spondyloarthritis Society. Axial SpA (AS) facts and figures [Internet]. 2020 [cited 2020 May 31]. Available from: https://nass.co.uk/about-as/as-facts-and-figures/
   Google Scholar
• Akkoc N, Khan MA. Is axial spondyloarthritis more common than rheumatoid arthritis? Curr Rheumatol Rep. 2020;22(9):54. doi: 10.1007/s11926-020-00934-3.
   PubMed Web of Science ®Google Scholar
• Strand V, Singh JA. Patient burden of axial spondyloarthritis. J Clin Rheumatol. 2017;23(7):383–391. doi: 10.1097/RHU.0000000000000589.
   PubMed Web of Science ®Google Scholar
• Sieper J, Poddubnyy D. Axial spondyloarthritis. Lancet. 2017;390(10089):73–84. doi: 10.1016/S0140-6736(16)31591-4.
   PubMed Web of Science ®Google Scholar
• Deodhar A, Strand V, Kay J, et al. The term “non-radiographic axial spondyloarthritis” is much more important to classify than to diagnose patients with axial spondyloarthritis. Ann Rheum Dis. 2016;75(5):791–794. doi: 10.1136/annrheumdis-2015-208852.
   PubMed Web of Science ®Google Scholar
• Poddubnyy D. Challenges in non-radiographic axial spondyloarthritis. Joint Bone Spine. 2023;90(1):105468. doi: 10.1016/j.jbspin.2022.105468.
   PubMed Web of Science ®Google Scholar
• de Winter JJ, van Mens LJ, van der Heijde D, et al. Prevalence of peripheral and extra-articular disease in ankylosing spondylitis versus non-radiographic axial spondyloarthritis: a meta-analysis. Arthritis Res Ther. 2016;18(1):196. doi: 10.1186/s13075-016-1093-z.
   PubMed Web of Science ®Google Scholar
• Redeker I, Callhoff J, Hoffmann F, et al. The prevalence and impact of comorbidities on patients with axial spondyloarthritis: results from a nationwide population-based study. Arthritis Res Ther. 2020;22(1):210. doi: 10.1186/s13075-020-02301-0.
   PubMed Web of Science ®Google Scholar
• Mease P, Deodhar A. Differentiating nonradiographic axial spondyloarthritis from its mimics: a narrative review. BMC Musculoskelet Disord. 2022;23(1):240. doi: 10.1186/s12891-022-05073-7.
   PubMed Web of Science ®Google Scholar
• Deodhar A, Machado PM, Mørup M, et al. Comparative efficacy and safety of bimekizumab in axial spondyloarthritis: a systematic literature review and network meta-analysis. Rheumatology. 2023;kead598. doi: 10.1093/rheumatology/kead598.
   PubMed Web of Science ®Google Scholar
• Hunter T, Sandoval D, Booth N, et al. Comparing symptoms, treatment patterns, and quality of life of ankylosing spondylitis and non-radiographic axial spondyloarthritis patients in the USA: findings from a patient and rheumatologist survey. Clin Rheumatol. 2021;40(8):3161–3167. doi: 10.1007/s10067-021-05642-6.
   PubMed Web of Science ®Google Scholar
• Sieper J, Hu X, Black CM, et al. Systematic review of clinical, humanistic, and economic outcome comparisons between radiographic and non-radiographic axial spondyloarthritis. Semin Arthritis Rheum. 2017;46(6):746–753. doi: 10.1016/j.semarthrit.2016.09.002.
   PubMed Web of Science ®Google Scholar
• Boonen A, Sieper J, van der Heijde D, et al. The burden of non-radiographic axial spondyloarthritis. Semin Arthritis Rheum. 2015;44(5):556–562. doi: 10.1016/j.semarthrit.2014.10.009.
   PubMed Web of Science ®Google Scholar
• López-Medina C, Ramiro S, Heijde D V D, et al. Characteristics and burden of disease in patients with radiographic and non-radiographic axial spondyloarthritis: a comparison by systematic literature review and meta-analysis. RMD Open. 2019;5(2):e001108. doi: 10.1136/rmdopen-2019-001108.
   PubMed Web of Science ®Google Scholar
• Ramiro S, Nikiphorou E, Sepriano A, et al. ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update. Ann Rheum Dis. 2022;82(9):e206. doi: 10.1136/ard-2023-223937.
   Web of Science ®Google Scholar
• Winthrop KL, Isaacs JD, Mease PJ, et al. Unmet need in rheumatology: reports from the advances in targeted therapies meeting, 2022. Ann Rheum Dis. 2023;82(5):594–598. doi: 10.1136/ard-2022-223528.
   PubMed Web of Science ®Google Scholar
• Kiltz U, Hoeper K, Hammel L, et al. Work participation in patients with axial spondyloarthritis: high prevalence of negative workplace experiences and long-term work impairment. RMD Open. 2023;9(1):e002663. doi: 10.1136/rmdopen-2022-002663.
   PubMed Web of Science ®Google Scholar
• NICE TA718. TA718 | Ixekizumab for treating axial spondyloarthritis | Guidance | NICE [Internet]. NICE; 2021 [cited 2022 Jan 12]. Available from: https://www.nice.org.uk/guidance/ta718
   Google Scholar
• Navarro-Compán V, Ermann J, Poddubnyy D. A glance into the future of diagnosis and treatment of spondyloarthritis. Ther Adv Musculoskelet Dis. 2022;14:1759720X221111611. doi: 10.1177/1759720X221111611.
   PubMed Web of Science ®Google Scholar
• Medicines and Healthcare Products Regulatory Agency. MHRA products | Bimzelx [Internet]. 2023 [cited 2023 Nov 16]. Available from: https://products.mhra.gov.uk/product/?product=BIMZELX
   Google Scholar
• Baraliakos X, Deodhar A, van der Heijde D, et al. Bimekizumab treatment in patients with active axial spondyloarthritis: 52-week efficacy and safety from the randomised parallel phase 3 BE MOBILE 1 and BE MOBILE 2 studies. Ann Rheum Dis. 2024;83(2):199–213. doi: 10.1136/ard-2023-224803.
   PubMed Web of Science ®Google Scholar
• Scottish Medicines Consortium. Bimekizumab (Bimzelx) SMC2616 [Internet]. Scottish Medicines Consortium; 2023 [cited 2024 Feb 26]. Available from: https://www.scottishmedicines.org.uk/medicines-advice/bimekizumab-bimzelx-axspa-abb-smc2616/
   Google Scholar
• NICE TA719. TA719 | Secukinumab for treating non-radiographic axial spondyloarthritis | guidance [Internet]. NICE; 2021 [cited 2022 Jan 12]. Available from: https://www.nice.org.uk/guidance/ta719
   Google Scholar
• Scottish Medicines Consortium. Ixekizumab (Taltz), SMC2440 [Internet]. Scottish Medicines Consortium; 2022 [cited 2023 Nov 14]. Available from: https://www.scottishmedicines.org.uk/medicines-advice/ixekizumab-taltz-full-smc2440/
   Google Scholar
• Scottish Medicines Consortium. Secukinumab (Cosentyx), SMC2308 [Internet]. Scottish Medicines Consortium; 2021 [cited 2023 Nov 14]. Available from: https://www.scottishmedicines.org.uk/medicines-advice/secukinumab-cosentyx-full-smc2308/
   Google Scholar
• Scottish Medicines Consortium. Secukinumab (Cosentyx), ID1159/16 [Internet]. Scottish Medicines Consortium; 2016 [cited 2023 Nov 14]. Available from: https://www.scottishmedicines.org.uk/medicines-advice/secukinumab-cosentyx-fullsubmission-115916/
   Google Scholar
• Deodhar A, Mease PJ, Reveille JD, et al. Frequency of axial spondyloarthritis diagnosis among patients seen by US rheumatologists for evaluation of chronic back pain. Arthritis Rheumatol. 2016;68(7):1669–1676. doi: 10.1002/art.39612.
   PubMed Web of Science ®Google Scholar
• EMC Bimekizumab. Bimzelx 160 mg solution for injection in pre-filled pen - summary of product characteristics (SmPC) - (emc) [Internet]. 2023 [cited 2023 Aug 9]. Available from: https://www.medicines.org.uk/emc/product/12834/smpc
   Google Scholar
• EMC Secukinumab. Cosentyx 150 mg solution for injection in pre-filled pen - summary of product characteristics (SmPC) - (emc) [Internet]. 2023 [cited 2023 Aug 9]. Available from: https://www.medicines.org.uk/emc/product/3669
   Google Scholar
• EMC ixekizumab. Taltz 80 mg solution for injection in pre-filled pen - summary of product characteristics (SmPC) - (emc) [Internet]. 2023 [cited 2023 Aug 9]. Available from: https://www.medicines.org.uk/emc/product/8199/smpc
   Google Scholar
• Fonseca D, Pinheiro FO, Rato M, et al. AB0483 can we predict which patients with spondyloarthritis will need dose escalation of secukinumab to 300 mg monthly? Ann Rheum Dis. 2021;80(Suppl 1):1269–1269. doi: 10.1136/annrheumdis-2021-eular.4001.
   Google Scholar
• Molto A, López-Medina C, den BF, et al. Efficacy of a tight-control and treat-to-target strategy in axial spondyloarthritis: results of the open-label, pragmatic, cluster-randomised TICOSPA trial. Ann Rheum Dis. 2021;80(11):1436–1444; [cited 2021 Jul 13]. Available from: https://ard.bmj.com/content/early/2021/05/05/annrheumdis-2020-219585 doi: 10.1136/annrheumdis-2020-219585.
   PubMed Web of Science ®Google Scholar
• Glintborg B, Loft AG, Omerovic E, et al. To switch or not to switch: results of a nationwide guideline of mandatory switching from originator to biosimilar etanercept. One-year treatment outcomes in 2061 patients with inflammatory arthritis from the DANBIO registry. Ann Rheum Dis. 2019;78(2):192–200. doi: 10.1136/annrheumdis-2018-213474.
   PubMed Web of Science ®Google Scholar
• Michelsen B, Lindström U, Codreanu C, et al. Drug retention, inactive disease and response rates in 1860 patients with axial spondyloarthritis initiating secukinumab treatment: routine care data from 13 registries in the EuroSpA collaboration. RMD Open. 2020;6(3):e001280. doi: 10.1136/rmdopen-2020-001280.
   PubMedGoogle Scholar
• Braun J, Davis J, Dougados M, et al. First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis. Ann Rheum Dis. 2006;65(3):316–320. doi: 10.1136/ard.2005.040758.
   PubMed Web of Science ®Google Scholar
• Borse RH, Kachroo S, Brown C, et al. Cost-effectiveness analysis of golimumab in the treatment of non-radiographic axial spondyloarthritis in Scotland. Rheumatol Ther. 2018;5(1):57–73. doi: 10.1007/s40744-018-0108-4.
   PubMed Web of Science ®Google Scholar
• Brandt J, Listing J, Sieper J, et al. Development and preselection of criteria for short term improvement after anti-TNF treatment in ankylosing spondylitis. Ann Rheum Dis. 2004;63(11):1438–1444. doi: 10.1136/ard.2003.016717.
   PubMed Web of Science ®Google Scholar
• Calin A, Garrett S, Whitelock H, et al. A new approach to defining functional ability in ankylosing spondylitis: the development of the bath ankylosing spondylitis functional index. J Rheumatol. 1994;21:2281–2285.
   PubMed Web of Science ®Google Scholar
• Machado P, Landewé R, Lie E, et al. Ankylosing spondylitis disease activity score (ASDAS): defining cut-off values for disease activity states and improvement scores. Ann Rheum Dis. 2011;70(1):47–53. doi: 10.1136/ard.2010.138594.
   PubMed Web of Science ®Google Scholar
• National Health Service. NHS England » national cost collection for the NHS [Internet]; 2022 [cited 2023 Nov 16]. Available from: https://www.england.nhs.uk/costing-in-the-nhs/national-cost-collection/
   Google Scholar
• PSSRU. Unit costs of health and social care programme (2022 – 2027) | the new home for the unit costs of health and social care report [Internet]; 2022 [cited 2023 Aug 9]. Available from: https://www.pssru.ac.uk/unitcostsreport/
   Google Scholar
• British National Formulary. MedicinesComplete—log in [Internet]; 2022 [cited 2023 Aug 9]. Available from: https://www.medicinescomplete.com/log-in/#/browse/bnf
   Google Scholar
• Corbett M, Soares M, Jhuti G, et al. Tumour necrosis factor-α inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis: a systematic review and economic evaluation. Health Technol Assess. 2016;20(9):1–334, v–vi. doi: 10.3310/hta20090.
   PubMed Web of Science ®Google Scholar
• Le QA, Kang JH, Lee S, et al. Cost-Effectiveness of treatment strategies with biologics in accordance with treatment guidelines for ankylosing spondylitis: a patient-level model. J Manag Care Spec Pharm. 2020;26(10):1219–1231. doi: 10.18553/jmcp.2020.26.10.1219.
   PubMed Web of Science ®Google Scholar
• Goeree R, Chiva-Razavi S, Gunda P, et al. Cost-effectiveness analysis of secukinumab in ankylosing spondylitis from the Canadian perspective. J Med Econ. 2019;22(1):45–52. doi: 10.1080/13696998.2018.1539400.
   PubMed Web of Science ®Google Scholar
• Purmonen T, Puolakka K, Mishra D, et al. Cost-effectiveness of secukinumab compared to other biologics in the treatment of ankylosing spondylitis in Finland. Clinicoecon Outcomes Res. 2019;11:159–168. doi: 10.2147/CEOR.S192235.
   PubMed Web of Science ®Google Scholar
• Jamal M, Kuijper TM, Hazes J, et al. A trial-based economic evaluation of the CaFaSpA referral strategy for axial spondyloarthritis. Scand J Rheumatol. 2023;53(1):1–9. doi: 10.1080/03009742.2023.2243081.
   PubMed Web of Science ®Google Scholar
• NICE. TA407 | Secukinumab for active ankylosing spondylitis after treatment with non-steroidal anti-inflammatory drugs or TNF-alpha inhibitors | guidance | NICE [Internet]. NICE; 2016 [cited 2022 Jan 12]. Available from: https://www.nice.org.uk/guidance/ta407
   Google Scholar
• Office for National Statistics. National life tables - life expectancy in the UK: 2018 to 2020 - Office for National Statistics [Internet]; 2020 [cited 2023 Nov 16]. Available from: https://www.ons.gov.uk/releases/nationallifetableslifeexpectancyintheuk2018to2020
   Google Scholar
• Golubev A. Does Makeham make sense? Biogerontology. 2004;5(3):159–167. doi: 10.1023/B:BGEN.0000031153.63563.58.
   PubMed Web of Science ®Google Scholar
• Bakland G, Gran JT, Nossent JC. Increased mortality in ankylosing spondylitis is related to disease activity. Ann Rheum Dis. 2011;70(11):1921–1925. doi: 10.1136/ard.2011.151191.
   PubMed Web of Science ®Google Scholar
• Elbasha EH, Chhatwal J. Myths and misconceptions of within-cycle correction: a guide for modelers and decision makers. PharmacoEconomics. 2016;34(1):13–22. doi: 10.1007/s40273-015-0337-0.
   PubMed Web of Science ®Google Scholar
• Baraliakos X, Deodhar A, Dougados M, et al. Safety and efficacy of bimekizumab in patients with active ankylosing spondylitis: three-year results from a phase IIb randomized controlled trial and its Open-Label extension study. Arthritis Rheumatol. 2022;74(12):1943–1958. doi: 10.1002/art.42282.
   PubMed Web of Science ®Google Scholar
• Stevens JW, Fletcher C, Downey G, et al. A review of methods for comparing treatments evaluated in studies that form disconnected networks of evidence. Res Synth Methods. 2018;9(2):148–162. doi: 10.1002/jrsm.1278.
   PubMed Web of Science ®Google Scholar
• Deodhar A, Kivitz A, Magrey M, et al. Op0023 a randomized, Double-Blind trial comparing secukinumab 300 mg and 150 mg at week 52 in patients with ankylosing spondylitis who did not achieve inactive disease during an initial 16 weeks of open-label treatment with secukinumab 150 mg. Ann Rheum Dis. 2022;81(Suppl 1):16–17. doi: 10.1136/annrheumdis-2022-eular.209.
   Google Scholar
• Song GG, Lee YH. Comparative efficacy and safety of secukinumab 75 mg, 150 mg, and 300 mg in patients with active ankylosing spondylitis. Int J Clin Pharmacol Ther. 2021;59(9):610–617. doi: 10.5414/CP203927.
   PubMed Web of Science ®Google Scholar
• Landewé R, Dougados M, Mielants H, et al. Physical function in ankylosing spondylitis is independently determined by both disease activity and radiographic damage of the spine. Ann Rheum Dis. 2009;68(6):863–867. doi: 10.1136/ard.2008.091793.
   PubMed Web of Science ®Google Scholar
• Ramiro S, Stolwijk C, van Tubergen A, et al. Evolution of radiographic damage in ankylosing spondylitis: a 12 year prospective follow-up of the OASIS study. Ann Rheum Dis. 2015;74(1):52–59. doi: 10.1136/annrheumdis-2013-204055.
   PubMed Web of Science ®Google Scholar
• Alava MH, Wailoo A, Chrysanthou G, et al. Measuring quality of life of patients with axial spondyloarthritis for economic evaluation. RMD Open. 2022;8(1):e001955. doi: 10.1136/rmdopen-2021-001955.
   PubMed Web of Science ®Google Scholar
• Machado P, Landewé R, Braun J, et al. A stratified model for health outcomes in ankylosing spondylitis. Ann Rheum Dis. 2011;70(10):1758–1764. doi: 10.1136/ard.2011.150037.
   PubMed Web of Science ®Google Scholar
• Hirano F, van der Heijde D, van Gaalen FA, et al. Determinants of the patient global assessment of well-being in early axial spondyloarthritis: 5-year longitudinal data from the DESIR cohort. Rheumatology. 2021;60(1):316–321. doi: 10.1093/rheumatology/keaa353.
   PubMed Web of Science ®Google Scholar
• Yeh S-T. Using trapezoidal rule for the area under a curve calculation. SUGI 27 Proceedings, Paper 229-27, April 2002.
   Google Scholar
• Hatswell AJ, Bullement A, Briggs A, et al. Probabilistic sensitivity analysis in cost-effectiveness models: determining model convergence in cohort models. Pharmacoeconomics. 2018;36(12):1421–1426. doi: 10.1007/s40273-018-0697-3.
   PubMed Web of Science ®Google Scholar
• Thom H. Deterministic and probabilistic analysis of a simple Markov model: how different could they be? Appl Health Econ Health Policy. 2022;20(3):447–449. doi: 10.1007/s40258-021-00700-1.
   PubMed Web of Science ®Google Scholar
• Dias S, Sutton AJ, Welton NJ, et al. Evidence synthesis for decision making 6: embedding evidence synthesis in probabilistic cost-effectiveness analysis. Med Decis Making. 2013;33:671–678.
   Google Scholar
• Scottish Medicines Consortium. Ixekizumab 80mg solution for injection in pre-filled syringe or pen (Taltz®). SMC2440, June 2022.
   Google Scholar
• Emery P, Van Keep M, Beard S, et al. Cost effectiveness of secukinumab for the treatment of active ankylosing spondylitis in the UK. Pharmacoeconomics. 2018;36(8):1015–1027. doi: 10.1007/s40273-018-0675-9.
   PubMed Web of Science ®Google Scholar
• Dubreuil M, Walsh JA, Deodhar A, et al. Real-world use of biologic disease-modifying anti‑rheumatic drugs in US patients with ankylosing spondylitis: persistence, factors associated with discontinuation, and dosing patterns. ISPOR | International Society for Pharmacoeconomics and Outcomes Research [Internet]; 2023 [cited 2024 Feb 6]. Available from: https://www.ispor.org/heor-resources/presentations-database/presentation/intl2023-3668/125411
   Google Scholar
• Anjohrin S, Song J, Abé C, et al. Real-world usage of biologic disease-Modifying anti-Rheumatic drugs in patients with axial spondyloarthritis in Germany. Value Health [Internet]; 2023;26(12):S300; [cited 2023 Dec 18]. Available from: https://www.ispor.org/heor-resources/presentations-database/presentation/euro2023-3785/131124
   Web of Science ®Google Scholar
• Sivera F, Núñez-Monje V, Campos-Fernández C, et al. Real-world experience with secukinumab in the entire axial spondyloarthritis spectrum. Front Med. 2023;10:1156557. doi: 10.3389/fmed.2023.1156557.
   Web of Science ®Google Scholar
• Olsen IC, Haavardsholm EA, Moholt E, et al. Nor-DMARD data management: implementation of data capture from electronic health records. Clin Exp Rheumatol. 2014;32:S-158–S-162.
   Web of Science ®Google Scholar
• Yahya F, Gaffney K, Hamilton L, et al. Tumour necrosis factor inhibitor survival and predictors of response in axial spondyloarthritis-findings from a United Kingdom cohort. Rheumatology. 2018;57(4):619–624. doi: 10.1093/rheumatology/kex457.
   PubMed Web of Science ®Google Scholar
• Glintborg B, Østergaard M, Krogh NS, et al. Clinical response, drug survival and predictors thereof in 432 ankylosing spondylitis patients after switching tumour necrosis factor α inhibitor therapy: results from the Danish nationwide DANBIO registry. Ann Rheum Dis. 2013;72(7):1149–1155. doi: 10.1136/annrheumdis-2012-201933.
   PubMed Web of Science ®Google Scholar
• Hebeisen M, Scherer A, Micheroli R, et al. Comparison of drug survival on adalimumab, etanercept, golimumab and infliximab in patients with axial spondyloarthritis. PLoS One. 2019;14(5):e0216746. doi: 10.1371/journal.pone.0216746.
   PubMed Web of Science ®Google Scholar
• Lassere MN, Rappo J, Portek IJ, et al. How many life years are lost in patients with rheumatoid arthritis? Secular cause-specific and all-cause mortality in rheumatoid arthritis, and their predictors in a long-term Australian cohort study. Intern Med J. 2013;43(1):66–72. doi: 10.1111/j.1445-5994.2012.02727.x.
   PubMed Web of Science ®Google Scholar
• Li Z, Khan MK, van der Linden SM, et al. HLA-B27, axial spondyloarthritis and survival. Ann Rheum Dis. 2023;82(12):1558–1567. doi: 10.1136/ard-2023-224434.
   PubMed Web of Science ®Google Scholar
• Manica SR, Sepriano A, Pimentel-Santos F, et al. Effectiveness of switching between TNF inhibitors in patients with axial spondyloarthritis: is the reason to switch relevant? Arthritis Res Ther. 2020;22(1):195. doi: 10.1186/s13075-020-02288-8.
   PubMed Web of Science ®Google Scholar
• Glintborg B, Lindström U, Giuseppe DD, et al. One-year treatment outcomes of secukinumab versus tumor necrosis factor inhibitors in spondyloarthritis: results from five Nordic biologic registries including more than 10,000 treatment courses. Arthritis Care Res. 2022;74(5):748–758. doi: 10.1002/acr.24523.
   Web of Science ®Google Scholar
• Haroon N, Inman RD, Learch TJ, et al. The impact of tumor necrosis factor α inhibitors on radiographic progression in ankylosing spondylitis. Arthritis Rheum. 2013;65(10):2645–2654. doi: 10.1002/art.3807023818109.
   PubMed Web of Science ®Google Scholar
• Machado PM, Landewé R, Heijde D V D Ankylosing spondylitis disease activity score (ASDAS): 2018 update of the nomenclature for disease activity states. Ann Rheum Dis. 2018;77(10):1539–1540. doi: 10.1136/annrheumdis-2018-213184.
   PubMed Web of Science ®Google Scholar
• Deodhar A, Blanco R, Dokoupilová E, et al. Improvement of signs and symptoms of nonradiographic axial spondyloarthritis in patients treated with secukinumab: primary results of a randomized, placebo-controlled phase III study. Arthritis Rheumatol. 2021;73(1):110–120. doi: 10.1002/art.41477.
   PubMed Web of Science ®Google Scholar
• Baeten D, Sieper J, Braun J, et al. Secukinumab, an interleukin-17A inhibitor, in ankylosing spondylitis. N Engl J Med. 2015;373(26):2534–2548. doi: 10.1056/NEJMoa1505066.
   PubMed Web of Science ®Google Scholar
• Deodhar A, van der Heijde D, Gensler LS, et al. Ixekizumab for patients with non-radiographic axial spondyloarthritis (Coast-X): a randomised, placebo-controlled trial. Lancet. 2020;395(10217):53–64. doi: 10.1016/S0140-6736(19)32971-X.
   PubMed Web of Science ®Google Scholar
• van der Heijde D, Cheng-Chung Wei J, Dougados M, et al. Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (Coast-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial. Lancet. 2018;392(10163):2441–2451. doi: 10.1016/S0140-6736(18)31946-9.
   PubMed Web of Science ®Google Scholar
• Kiltz U, Baraliakos X, Brandt-Jrgens J, et al. Evaluation of the nonsteroidal anti-inflammatory drug-sparing effect of secukinumab in patients with ankylosing spondylitis: multicenter, randomised, double-blind, phase IV study. ACR meeting abstracts [Internet]; 2021 [cited 2024 Jan 31]. Available from: https://acrabstracts.org/abstract/evaluation-of-the-nonsteroidal-anti-inflammatory-drug-sparing-effect-of-secukinumab-in-patients-with-ankylosing-spondylitis-multicenter-randomised-double-blind-phase-iv-study/
   Google Scholar
• Xue Y, Hu J, Liu D, et al. Efficacy and safety of ixekizumab in Chinese patients with radiographic axial spondyloarthritis: 16-week results from a phase 3 study. ACR meeting abstracts [Internet]; 2022 [cited 2024 Jan 31]. Available from: https://acrabstracts.org/abstract/efficacy-and-safety-of-ixekizumab-in-chinese-patients-with-radiographic-axial-spondyloarthritis-16-week-results-from-a-phase-3-study/
   Google Scholar